InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
Maniana Free
02/10/21 11:22 PM
profile icon
Dougie1128 Free
02/05/21 11:53 AM
profile icon
Mrvince Free
04/03/20 2:02 PM
profile icon
Value_Investor Free
01/07/19 4:12 PM
profile icon
Value_Investor Free
01/02/19 12:16 PM
profile icon
Value_Investor Free
12/21/18 11:29 AM
profile icon
Value_Investor Free
12/18/18 12:30 PM
profile icon
Value_Investor Free
12/07/18 4:41 PM
profile icon
Value_Investor Free
12/07/18 4:35 PM
profile icon
Value_Investor Free
12/07/18 1:59 PM
profile icon
Value_Investor Free
11/28/18 11:16 AM
profile icon
Value_Investor Free
08/12/18 2:42 PM
profile icon
Value_Investor Free
08/04/18 4:30 PM
profile icon
Value_Investor Free
08/01/18 9:54 PM
profile icon
SC777 Free
07/31/18 12:15 PM
profile icon
Value_Investor Free
07/31/18 10:18 AM
profile icon
Value_Investor Free
07/30/18 10:27 AM
profile icon
Value_Investor Free
07/08/18 11:58 PM
profile icon
Value_Investor Free
07/03/18 10:44 AM
profile icon
Value_Investor Free
07/02/18 10:51 AM
profile icon
Value_Investor Free
06/30/18 1:00 PM
profile icon
Value_Investor Free
06/29/18 11:51 AM
profile icon
Value_Investor Free
06/28/18 11:28 AM
profile icon
DFRANK1970 Free
06/27/18 7:16 PM
profile icon
Value_Investor Free
06/27/18 6:17 PM
profile icon
ClayTrader Free
06/27/18 5:05 PM
profile icon
TenKay Free
06/27/18 4:37 PM
profile icon
Inoviorulez Free
06/27/18 1:13 PM
profile icon
GreekSeas0ning Free
06/27/18 12:23 PM
profile icon
Value_Investor Free
06/22/18 4:27 PM
profile icon
enforcer1 Terminated
06/19/18 10:38 AM
profile icon
Value_Investor Free
06/12/18 11:51 PM
profile icon
ClayTrader Free
06/12/18 5:20 PM
profile icon
Stockcaller Free
06/12/18 10:00 AM
profile icon
Stockcaller Free
06/11/18 7:05 PM
profile icon
Value_Investor Free
06/11/18 6:40 PM
profile icon
Stockcaller Free
06/11/18 5:25 PM
profile icon
Stockcaller Free
06/10/18 11:48 PM
profile icon
Stockcaller Free
06/10/18 5:11 PM
profile icon
Stockcaller Free
06/10/18 1:35 PM
profile icon
Value_Investor Free
06/10/18 12:54 PM
profile icon
Stockcaller Free
06/09/18 6:06 PM
profile icon
Value_Investor Free
06/09/18 3:41 PM
profile icon
Stockcaller Free
06/09/18 2:46 AM
profile icon
Value_Investor Free
06/08/18 4:59 PM
profile icon
Stockcaller Free
06/08/18 1:45 PM
profile icon
enforcer1 Terminated
06/08/18 1:04 PM
profile icon
Stockcaller Free
06/08/18 12:19 PM

Anthera Pharmaceuticals, Inc. (ANTH) RSS Feed

Followers
57
Posters
271
Posts (Today)
0
Posts (Total)
2495
Created
03/01/10
Type
Free
Moderators

 


 Anthera Pharmaceuticals Inc.     


                                              Nasdaq: ANTH


 

Anthera Pharmaceuticals is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company has two product candidates in development.

 

Sollpura is Anthera’s novel biotechnology-derived pancreatic enzyme replacement therapy for the potential treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

Blisibimod is Anthera’s BAFF inhibitor for the potential treatment of systemic lupus erythematosus and IgA nephropathy.


Pipeline



                            Contact Info                                                                           
                                                                           

Anthera Pharmaceuticals, Inc. 

25801 Industrial Blvd, Suite B • Hayward, CA 94545



Press Contact: pr@anthera.com


Business Development: bd@anthera.com


 Vendors: ap@anthera.com


 Website: www.anthera.com

 

------>>Latest Developments<<-----

December 06, 2016

J. Craig Thompson promoted to Chief Executive Officer and appointed to the Board of Directors Paul F. Truex appointed as Executive Chairman of the Board Dr. Christopher Henney stepped down as Chairman ...

1
 
         
___________________________________________________________________________________________________________________________________________
Outstanding Share Data
October 31 ,2016,the Company had 41,955,126 common shares issued and outstanding
July 31,2016 the Company had 41,427,352 common shares issued and outstanding
April 27,2016 the Company had 40,987,145 common shares issued and outstanding
February 29,2016 the Company had 40,004,037 common shares issued and outstanding
November 1,2015 the Company had 39,875,405 common shares issued and outstanding
August 1,2015 the Company had 39,703,998 common shares issued and outstanding
May 1,2015 the Company had 35,816,364 common shares issued and outstanding
February 28,2015 the Company had 29,091,773 common shares issued and outstanding
November 10,2014 the Company had 22,939,553 common shares issued and outstanding
____________________________________________________________________________________________________________________________________________

MAJOR HOLDERS


68% of the outstanding owned by these longs

Outstanding 42mil minus Major ownership of 28.5mil = 13.5mil free trading float


28.5mil Major Holders in this,15mil Institutions,7.5mil Direct Holders,6mil Mutual Funds= 68% of 42mil os 


http://www.barrons.com/quote/stock/us/xnas/anth?mod=DNH_S

________________________________________________________________


http://finance.yahoo.com/q?s=ANTH

   Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation,

including cardiovascular and autoimmune diseases. We currently have a Phase 2 clinical program, blisibimod.It was just recently approved by FDA to move into

PHASE 3

 

   Blisibimod targets elevated levels of B-cell activating factor (BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren's Syndrome, Graves' Disease and others.


  It has taken the lupus research community over 50 years to produce a new therapy. Although it is now a year old, Benlysta (belimumab),

now marketed by GlaxoSmithKline and Human Genome Sciences, is the first human monoclonal antibody for the treatment

of lupus.




  Benlysta had a slow take-off grossing $59.2 million in sales in the last three quarters of 2011, but it was approved in numerous

countries by year's end.
Estimated sales for Benlysta in 2012 are said to be about $230 million, with first annual profits likely by 2015.


  The surprisingly slow uptake of Benlysta allows for blisibimod to develop into a promising drug as

it currently has more desirable features than that of Benlysta.


Blisibimod has a dosing regimen of one injection weekly, compared to that of Benlysta which requires a

series of dosing before the maintenance dose begins. Also, Benlysta has limitations on usage pertaining to

specific patient populations and has not been studied in combination with other biologics.

These attributes of blisibimod including a different mechanism of action, will set it apart from

Benlysta, Global Data concludes.

 

 

Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
ANTH Latest News
  • No Recent News Available for this company!
New Post